ProfileGDS5678 / 1450590_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 37% 37% 37% 36% 35% 41% 36% 49% 36% 38% 38% 39% 38% 37% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8921237
GSM967853U87-EV human glioblastoma xenograft - Control 22.8454337
GSM967854U87-EV human glioblastoma xenograft - Control 32.8442537
GSM967855U87-EV human glioblastoma xenograft - Control 42.7753836
GSM967856U87-EV human glioblastoma xenograft - Control 52.7601735
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0413541
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8844436
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1474449
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7993936
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.8558338
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.8484138
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8492239
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8651438
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8487637